Overview
Kuros Biosciences AG is a Swiss-based biotechnology company specializing in the development of innovative solutions for tissue repair and regeneration. The company's primary industry is healthcare, with a specific focus on orthobiologics. Kuros Biosciences is engaged in two key projects: the development of MagnetOs, a bone graft substitute for use in spinal fusion, and Fibrin-PTH, a product designed to heal bone defects.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Kuros Biosciences AG as of June 30, 2025 is 103.35 MM.
- The operating income for Kuros Biosciences AG as of June 30, 2025 is 3.85 MM.
- The net income for Kuros Biosciences AG as of June 30, 2025 is -6.07 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 103.35 | 3.85 | -6.07 |
2025-03-31 | 89.45 | 1.98 | -5.18 |
2024-12-31 | 75.56 | 0.11 | -4.29 |
2024-06-30 | 56.38 | -0.80 | -8.91 |
2024-03-31 | 44.97 | -2.94 | -11.32 |
2023-12-31 | 33.56 | -5.09 | -13.73 |
2023-09-30 | 27.00 | -10.33 | -14.84 |
2023-06-30 | 20.43 | -11.99 | -15.95 |
2023-03-31 | 19.21 | -10.92 | -15.27 |
2022-12-31 | 17.99 | -9.85 | -14.60 |
2022-09-30 | 16.57 | -9.77 | -12.87 |
2022-06-30 | 15.15 | -9.70 | -11.14 |
2022-03-31 | 14.48 | -9.23 | -9.34 |
2021-12-31 | 13.81 | -8.77 | -7.54 |
2021-09-30 | 12.82 | -7.82 | -6.66 |
2021-06-30 | 11.83 | -6.87 | -5.78 |
2021-03-31 | 7.93 | -9.33 | -8.65 |
2020-12-31 | 4.04 | -11.79 | -11.52 |
2020-09-30 | 3.49 | -12.10 | -11.69 |
2020-06-30 | |||
2020-03-31 |
Income Statement: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | -0.12 | |
2024-06-30 | -0.31 | -0.31 |
2024-03-31 | -0.34 | -0.35 |
2023-12-31 | -0.38 | |
2023-09-30 | -0.41 | -0.42 |
2023-06-30 | -0.45 | -0.45 |
2023-03-31 | -0.44 | -0.44 |
2022-12-31 | -0.43 | -0.43 |
2022-09-30 | -0.35 | -0.35 |
2022-06-30 | ||
2022-03-31 | -0.28 | -0.28 |
2021-12-31 | -0.23 | -0.23 |
2021-09-30 | -0.20 | -0.20 |
2021-06-30 | ||
2021-03-31 | -0.26 | -0.26 |
2020-12-31 | -0.47 | -0.47 |
2020-09-30 | -0.53 | -0.53 |
2020-06-30 | -0.61 | -0.60 |
2020-03-31 | -0.65 | -0.65 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Kuros Biosciences AG as of June 30, 2025 is 0.82 MM.
- The cash from investing activities for Kuros Biosciences AG as of June 30, 2025 is -1.49 MM.
- The cash from financing activities for Kuros Biosciences AG as of June 30, 2025 is 1.58 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 0.82 | -1.49 | 1.58 |
2025-03-31 | 1.98 | -1.30 | 1.46 |
2024-12-31 | 3.14 | -1.11 | 1.34 |
2024-06-30 | -2.46 | -0.92 | 0.73 |
2024-03-31 | -5.65 | -0.62 | 0.28 |
2023-12-31 | -8.84 | -0.33 | -0.17 |
2023-09-30 | -8.06 | -0.37 | 1.46 |
2023-06-30 | -7.27 | -0.42 | 3.08 |
2023-03-31 | -7.31 | -0.41 | 3.15 |
2022-12-31 | -7.35 | -0.40 | 3.22 |
2022-09-30 | -9.42 | -0.31 | 4.64 |
2022-06-30 | -11.48 | -0.21 | 6.06 |
2022-03-31 | -8.47 | -0.29 | 6.07 |
2021-12-31 | -5.46 | -0.37 | 6.08 |
2021-09-30 | -5.05 | -0.33 | 11.52 |
2021-06-30 | -4.65 | -0.28 | 16.95 |
2021-03-31 | -6.95 | -0.25 | 17.02 |
2020-12-31 | -9.24 | -0.22 | 17.08 |
2020-09-30 | -9.55 | -0.23 | 14.80 |
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 | |||
2020-06-30 | |||
2020-03-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 | ||
2020-06-30 | ||
2020-03-31 |
Management Effectiveness
- The roa for Kuros Biosciences AG as of June 30, 2025 is -0.06.
- The roe for Kuros Biosciences AG as of June 30, 2025 is -0.07.
- The roic for Kuros Biosciences AG as of June 30, 2025 is -0.07.
- The croic for Kuros Biosciences AG as of June 30, 2025 is 0.06.
- The ocroic for Kuros Biosciences AG as of June 30, 2025 is 0.05.
Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
2025-06-30 | -0.06 | -0.07 | -0.07 | 0.06 | 0.05 |
2025-03-31 | -0.06 | -0.07 | -0.07 | 0.06 | 0.05 |
2024-12-31 | -0.12 | -0.16 | -0.14 | -0.04 | -0.04 |
2024-06-30 | -0.18 | ||||
2024-03-31 | -0.20 | ||||
2023-12-31 | -0.25 | -0.12 | |||
2023-09-30 | -0.24 | -0.07 | |||
2023-06-30 | -0.22 | ||||
2023-03-31 | -0.21 | ||||
2022-12-31 | |||||
2022-09-30 | 0.00 | ||||
2022-06-30 | 0.00 | 0.00 | |||
2022-03-31 | 0.00 | ||||
2021-12-31 | 0.00 | ||||
2021-09-30 | 0.00 | 0.00 | |||
2021-06-30 | -0.07 | -0.07 | 0.14 | -0.05 | |
2021-03-31 | -0.11 | -0.12 | -0.10 | 0.11 | -0.08 |
2020-12-31 | -0.13 | -0.15 | -0.13 | 0.09 | -0.11 |
2020-09-30 | -0.13 | -0.15 | -0.13 | 0.06 | -0.11 |
2020-06-30 | -0.15 | -0.17 | -0.16 | 0.03 | -0.13 |
2020-03-31 | -0.14 | -0.16 | -0.15 | 0.03 | -0.14 |
Gross Margins
- The gross margin for Kuros Biosciences AG as of June 30, 2025 is 0.89.
- The net margin for Kuros Biosciences AG as of June 30, 2025 is -0.06.
- The operating margin for Kuros Biosciences AG as of June 30, 2025 is 0.00.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
2025-06-30 | 0.89 | -0.06 | 0.00 |
2025-03-31 | 0.89 | -0.06 | 0.00 |
2024-12-31 | 0.88 | -0.17 | -0.09 |
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | -0.78 | -0.76 | |
2023-06-30 | -0.78 | -0.76 | |
2023-03-31 | -0.80 | -0.76 | |
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | 0.00 | 0.00 | |
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | 0.74 | -0.49 | -0.58 |
2021-03-31 | 0.66 | -1.09 | -1.18 |
2020-12-31 | -0.58 | -2.85 | -2.89 |
2020-09-30 | 0.04 | -3.35 | -3.46 |
2020-06-30 | 0.83 | -4.03 | -4.21 |
2020-03-31 | 0.82 | -4.20 | -4.32 |
Identifiers and Descriptors
Central Index Key (CIK) |